Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Andrew Callos reported proposed sales of Common Stock via a Form 144. The notice lists 72,190 shares tied to an exercise of stock options (04/15/2026) and 7,449 shares tied to Restricted Stock Units (03/15/2026). The filing also lists multiple completed 10b5-1 sales in Feb–Mar 2026, including sales of 15,000 shares on 03/05/2026.
Cytokinetics EVP of Research & Development Fady Malik exercised stock options and sold shares on April 7, 2026. He exercised options covering 3,500 shares at $7.80 and 1,000 shares at $10.60 per share, then sold a total of 4,500 common shares in open-market transactions.
The sales involved 3,500 shares at $65.21 and 1,000 shares at $64.75 per share. After these exercise-and-sell transactions, he directly holds 153,902 shares of Cytokinetics common stock. This filing reflects a routine combination of option exercises and partial share sales by a senior executive.
CYTK filing reports an intended sale of 22,000 shares of Common Stock on 04/07/2026 following the exercise of stock options for cash. The filing lists brokerage placement with Morgan Stanley Smith Barney LLC and discloses prior sales by Fady Malik of 12,033 and 2,907 shares on 03/17/2026 and 03/09/2026, respectively, with disclosed gross proceeds.
Insider Robert Blum reported planned and recent disposals of Cytek Biosciences common stock via Form 144. The filing lists 45,000 Restricted Stock Units to be sold and shows two reported disposals in the past three months: 36,601 shares for $2,274,752.15 and 7,931 shares for $481,570.32. The cover lists an aggregate value of $2,965,950.00 and a figure of 123,162,807 shown alongside the 04/01/2026 date.
Cytokinetics Inc President & CEO Robert I. Blum sold 7,500 shares of Common Stock in an open-market transaction at $66.63 per share. Following the sale, he directly holds 422,830 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
CYTK filing notifies a proposed sale of 3,639 Restricted Stock Units dated 03/06/2026. The filing also lists multiple 10b5-1 dispositions by Andrew Callos between 01/02/2026 and 03/18/2026, including sales of 15,000 shares on 03/05/2026 and other dated transactions with reported proceeds.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 3,639 shares of Common Stock in an open-market transaction at $65.00 per share. The sale occurred on March 31, 2026. After this transaction, he continues to hold 66,004 shares of Cytokinetics Common Stock directly.
The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A for Cytokinetics Inc. The amendment states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Cytokinetics Common Stock, representing 0% of the class as shown in the filing dated 03/13/2026 with a signature on 03/26/2026. The filing explains certain subsidiaries and business divisions will report ownership separately in reliance on SEC Release No. 34-39538.
Cytokinetics EVP and CFO Sung Lee reported an open-market sale of 4,935 shares of Common Stock at $62.15 per share. According to the footnote, this was a company-compelled sell-to-cover transaction to satisfy tax withholding obligations from RSU vesting, rather than a discretionary sale. After the transaction, Lee directly holds 87,127 shares, indicating he retains a substantial equity position.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported a company‑compelled sale of 8,542 shares of Common Stock at $62.15 per share on March 17, 2026 to cover tax withholding from RSU vesting.
These sell‑to‑cover transactions were executed in two tranches and are tied to compensation, rather than discretionary trading. Following the sales, Callos directly holds 71,573 Cytokinetics shares, maintaining a substantial equity stake in the company.